Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

  • STATUS
    Recruiting
  • End date
    Apr 30, 2024
  • participants needed
    900
  • sponsor
    Shanghai Pharmaceuticals Holding Co., Ltd
Updated on 10 May 2022

Summary

The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.

Details
Condition Essential Hypertension
Treatment Valsartan, SPH3127 tablet
Clinical Study IdentifierNCT05359068
SponsorShanghai Pharmaceuticals Holding Co., Ltd
Last Modified on10 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female of age ≥18 years
Diagnosed with mild-moderate essential hypertension
Participant has understood the study-required procedures, voluntarily signed informed consent

Exclusion Criteria

Diagnosed with secondary hypertension, suspected grade 3 hypertension, acute hypertension, or at risk when current antihypertensive therapy discontinued
Suffered by severe heart disease within 6 months
Suffered by severe cerebrovascular disease within 6 months
Suffered by severe or malignant retinopathy
Out of controlled diabetes
History of malignant tumor
History of mental disorder
Subject is planning or in use of other antihypertensive drugs or other drugs may affect blood pressure during the trial
Alcohol or drug abuse
Pregnant, lactating women or subject is planning to pregnant within 6 months after the trial
Assessed by the investigators as unsuitable for participating in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note